Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.
暂无分享,去创建一个
G. Criner | J. Bourbeau | B. Celli | Joseph Ornelas | M. Foreman | M. Dransfield | P. Hernandez | P. Camp | R. Mularski | N. Hanania | M. Stickland | N. Marchetti | D. Ouellette | R. Diekemper | D. Marciniuk | D. Goodridge | J. Road | B. Ireland | K. Curren | M. Balter | M. Bhutani | G. Dechman | S. Fiel | J. Ornelas
[1] M. Petticrew,et al. Developing and evaluating complex interventions: the new Medical Research Council guidance , 2008, BMJ : British Medical Journal.
[2] M. Cazzola,et al. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. , 2011, Trends in pharmacological sciences.
[3] L. Allegra,et al. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. , 1996, Respiration; international review of thoracic diseases.
[4] G. Pugliese,et al. Severe Streptococcus pyogenes Infections, United Kingdom, 2003–2004 , 2008, Emerging infectious diseases.
[5] P. Shekelle,et al. Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society , 2011, Annals of Internal Medicine.
[6] M. Cazzola,et al. An update on bronchodilators in Phase I and II clinical trials , 2012, Expert opinion on investigational drugs.
[7] L Goldman,et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments) , 1996, American journal of respiratory and critical care medicine.
[8] C. Cooper,et al. The role of long-acting bronchodilators in the management of stable COPD. , 2004, Chest.
[9] Martin Hefford,et al. Results of a telehealth-enabled chronic care management service to support people with long-term conditions at home , 2012, Journal of telemedicine and telecare.
[10] Anne Holland,et al. Telehealth reduces hospital admission rates in patients with COPD. , 2013, Journal of physiotherapy.
[11] K. Traynor. Dueling draft bills address tracking of pharmaceuticals. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[12] J. Bourbeau,et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis , 2006, Thorax.
[13] Sean Keenan,et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. , 2007, Canadian respiratory journal.
[14] J. V. van Noord,et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease , 2010, Thorax.
[15] Malbea A Lapete,et al. Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) , 2004 .
[16] M. Grillage,et al. Long‐Term Oral Carbocisteine Therapy in Patients with Chronic Bronchitis. A Double Blind Trial with Placebo Control , 1985, The British journal of clinical practice.
[17] F. Martinez,et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. , 2013, The Lancet. Respiratory medicine.
[18] S. Campbell,et al. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. , 1999, Archives of internal medicine.
[19] J. Alonso,et al. The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease. , 2012, Archivos de bronconeumologia.
[20] C. Crim,et al. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study. , 2012, Clinical therapeutics.
[21] N. Tzanakis,et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. , 2007, Respiratory medicine.
[22] N. Zhong,et al. Positive benefits of theophylline in a randomized, double‐blind, parallel‐group, placebo‐controlled study of low‐dose, slow‐release theophylline in the treatment of COPD for 1 year , 2006, Respirology.
[23] W. Tam,et al. Effect of early pulmonary rehabilitation on health care utilization and health status in patients hospitalized with acute exacerbations of COPD , 2011, Respirology.
[24] R. Mehta,et al. Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol Alone and in Combination: A Randomized Crossover Trial , 2012, PloS one.
[25] E. Toft,et al. Cost-utility analysis of a telerehabilitation program: a case study of COPD patients. , 2012, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.
[26] H. Bloomfield,et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. , 2010, American journal of respiratory and critical care medicine.
[27] J. Lammers,et al. Effect of an action plan with ongoing support by a case manager on exacerbation-related outcome in patients with COPD: a multicentre randomised controlled trial , 2011, Thorax.
[28] F. Martinez,et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol , 2012, European Respiratory Journal.
[29] Meilan K. Han,et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. , 2014, The New England journal of medicine.
[30] P. Poole,et al. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.
[31] T. Seemungal,et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations , 2002, Thorax.
[32] N. Zhong,et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study , 2008, The Lancet.
[33] Janita Pak-Chun Chau,et al. A feasibility study to investigate the acceptability and potential effectiveness of a telecare service for older people with chronic obstructive pulmonary disease , 2012, Int. J. Medical Informatics.
[34] K. Fong,et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.
[35] D. Postma,et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis , 1999, Thorax.
[36] Meilan K. Han,et al. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] J. Vestbo,et al. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study , 2002, Thorax.
[38] R. Dahl,et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. , 2013, Respiratory medicine.
[39] W. Bailey,et al. Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .
[40] M. Cazzola,et al. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. , 2003, Respiratory medicine.
[41] P. Chanez,et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial , 2007 .
[42] S. Pocock,et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. , 2009, Pulmonary pharmacology & therapeutics.
[43] B. Make,et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.
[44] A. Buist,et al. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: An 85-day multicenter trial , 1994 .
[45] M. A. Martínez-García,et al. Eficacia de un programa específico para pacientes con EPOC que presentan frecuentes agudizaciones , 2006 .
[46] S. Rennard,et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. , 1996, Chest.
[47] Gordon H Guyatt,et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease , 1996, The Lancet.
[48] J. Castro‐Rodriguez,et al. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. , 2012, Pulmonary pharmacology & therapeutics.
[49] C. Trott,et al. The effect of a respiratory home nurse intervention in patients with chronic obstructive pulmonary disease (COPD). , 1999, Australian and New Zealand journal of medicine.
[50] C. Cates,et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.
[51] W. MacNee,et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.
[52] T. Lasserson,et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2012, The Cochrane database of systematic reviews.
[53] John Connett,et al. Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[54] T. Jørgensen,et al. The effectiveness of smoking cessation groups offered to hospitalised patients with symptoms of exacerbations of chronic obstructive pulmonary disease (COPD) , 2008, The clinical respiratory journal.
[55] M. Cazzola,et al. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. , 2010, Pulmonary pharmacology & therapeutics.
[56] B. Beghé,et al. Inhaled corticosteroids in COPD: pros and cons. , 2013, Current drug targets.
[57] D. Warm,et al. Does Home Telemonitoring after Pulmonary Rehabilitation Reduce Healthcare Use in Optimized COPD?? A Pilot Randomized Trial , 2011, COPD.
[58] G. Duvel. The study group. , 1980 .
[59] B. Smith,et al. Long-acting beta2-agonists for chronic obstructive pulmonary disease. , 2000, The Cochrane database of systematic reviews.
[60] D. Hui,et al. Roflumilast in Asian patients with COPD: A randomized placebo‐controlled trial , 2011, Respirology.
[61] B. Yawn,et al. Inflammation in COPD: implications for management. , 2012, The American journal of medicine.
[62] R. Murray,et al. Smoking cessation in chronic obstructive pulmonary disease. , 2009, Respiratory medicine.
[63] M. Friedman. A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease. , 1996, The American journal of medicine.
[64] Michael A. Kuskowski,et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. , 2000, American journal of respiratory and critical care medicine.
[65] D. Halpin,et al. A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. , 2011, Primary care respiratory journal : journal of the General Practice Airways Group.
[66] V. Brusasco. Reducing cholinergic constriction: the major reversible mechanism in COPD , 2006, European Respiratory Review.
[67] T. Seemungal,et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.
[68] F. Gallefoss. The effects of patient education in COPD in a 1-year follow-up randomised, controlled trial. , 2004, Patient education and counseling.
[69] R. Pauwels,et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. , 2004, Respiratory medicine.
[70] R. Wootton. Twenty years of telemedicine in chronic disease management – an evidence synthesis , 2012, Journal of telemedicine and telecare.
[71] N. Gross,et al. Inhalation by Nebulization of Albuterol-Ipratropium Combination (Dey Combination) Is Superior to Either Agent Alone in the Treatment of Chronic Obstructive Pulmonary Disease , 1998, Respiration.
[72] M. Lainscak,et al. Discharge coordinator intervention prevents hospitalizations in patients with COPD: a randomized controlled trial. , 2012, Journal of the American Medical Directors Association.
[73] S. Johnston,et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. , 2006, American journal of respiratory and critical care medicine.
[74] Reinier Akkermans,et al. Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial , 2012, BMJ : British Medical Journal.
[75] E. Bleecker,et al. Results of a multicenter study of nebulized inhalant bronchodilator solutions. , 1996, The American journal of medicine.
[76] Moon Fai Chan,et al. Effects of nurse-initiated telephone follow-up on self-efficacy among patients with chronic obstructive pulmonary disease. , 2005, Journal of advanced nursing.
[77] K. Traynor. Fluticasone-vilanterol combination approved for COPD. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[78] L. Davies,et al. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial , 1999, The Lancet.
[79] F. Martinez,et al. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial. , 2013, Respiratory medicine.
[80] Y. Lacasse,et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. , 2015, The Cochrane database of systematic reviews.
[81] F. Martinez,et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.
[82] R. Wood‐Baker,et al. Written action plans in chronic obstructive pulmonary disease increase appropriate treatment for acute exacerbations , 2006, Respirology.
[83] G. Boman,et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. , 1983, European journal of respiratory diseases.
[84] J. L. Alonso,et al. The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease. , 2012 .
[85] P. Frith,et al. Self management for patients with chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.
[86] J. Yates,et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.
[87] D. Postma,et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. , 2009, Annals of internal medicine.
[88] R. Mehta,et al. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study , 2013, International journal of chronic obstructive pulmonary disease.
[89] Christopher B Cooper,et al. Airflow obstruction and exercise. , 2009, Respiratory medicine.
[90] P. Poole,et al. Does early pulmonary rehabilitation reduce acute health‐care utilization in COPD patients admitted with an exacerbation? A randomized controlled study , 2009, Respirology.
[91] J. Wedzicha,et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. , 2013, The Lancet. Respiratory medicine.
[92] H. Magnussen,et al. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. , 1995, The European respiratory journal.
[93] J. Kleijnen,et al. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials , 2009, European Respiratory Journal.
[94] J. Walters,et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. , 2010, The Cochrane database of systematic reviews.
[95] A. Jarab,et al. Impact of pharmaceutical care on health outcomes in patients with COPD , 2012, International Journal of Clinical Pharmacy.
[96] P. Tarsia,et al. Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. , 1997, Journal of chemotherapy.
[97] Richard Casaburi,et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. , 2007, Chest.
[98] M. Etminan,et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. , 2006, Journal of the American College of Cardiology.
[99] J. Walters,et al. Effects of telephone health mentoring in community-recruited chronic obstructive pulmonary disease on self-management capacity, quality of life and psychological morbidity: a randomised controlled trial , 2013, BMJ Open.
[100] E. Seydel,et al. Cost-effectiveness of an intensive smoking cessation intervention for COPD outpatients. , 2012, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.
[101] W. Dejsomritrutai,et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. , 2004, Chest.
[102] L. Allegra,et al. Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. , 1990, Respiration; international review of thoracic diseases.
[103] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[104] C. Sanguinetti,et al. N-Acetylcysteine Reduces the Exacerbation Rate in Patients with Moderate to Severe COPD , 1999, Respiration.
[105] M. Polkey,et al. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study , 2004, BMJ : British Medical Journal.
[106] C. Vogelmeier,et al. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group, multicentre study , 2009, Respiratory research.
[107] Mark Petticrew,et al. When are complex interventions 'complex'? When are simple interventions 'simple'? , 2011, European journal of public health.
[108] Martin Knapp,et al. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial , 2013, BMJ.
[109] J. Bourbeau,et al. The burden of COPD in Canada: results from the Confronting COPD survey. , 2003, Respiratory medicine.
[110] C. Grassi,et al. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis , 1976, European Journal of Clinical Pharmacology.
[111] Peter J. Barnes,et al. Inhaled Corticosteroids in COPD: A Controversy , 2010, Respiration.
[112] P. B. Koff,et al. Proactive integrated care improves quality of life in patients with COPD , 2009, European Respiratory Journal.
[113] F. Martinez,et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.
[114] M. Decramer,et al. Integrated care prevents hospitalisations for exacerbations in COPD patients , 2006, European Respiratory Journal.
[115] E. Bateman,et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study , 2012, European Respiratory Journal.
[116] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[117] F. Weaver,et al. Impact of Pneumococcal Vaccination on Pneumonia Rates in Patients with COPD and Asthma , 2007, Journal of General Internal Medicine.
[118] P. Calverley. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. , 2004, Proceedings of the American Thoracic Society.
[119] A. Anzueto,et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. , 2008, Respiratory medicine.
[120] S. Biswal,et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress , 2011, Biochemical and biophysical research communications.
[121] F. Maltais,et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials , 2007, Thorax.
[122] C. Whitney,et al. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). , 2010, MMWR. Morbidity and mortality weekly report.
[123] P. Barnes. New Therapies for Chronic Obstructive Pulmonary Disease , 2010, Medical Principles and Practice.
[124] P. Poole,et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.
[125] Alison Lesley Weightman,et al. Grading evidence and recommendationsfor public health interventions: developing and pilotinga framework , 2005 .
[126] F. Maltais,et al. Self-management reduces both short- and long-term hospitalisation in COPD , 2005, European Respiratory Journal.
[127] A. Church,et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. , 2013, Respiratory medicine.
[128] J. B. Rasmussen,et al. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. , 1988, The European respiratory journal.
[129] W. MacNee,et al. Effect of 6 Months of Erythromycin Treatment on Inflammatory Cells in Induced Sputum and Exacerbations in Chronic Obstructive Pulmonary Disease , 2010, Respiration.
[130] L. Kuramoto,et al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. , 2008, Respiratory medicine.
[131] J. Cramer,et al. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. , 2007, Canadian respiratory journal.
[132] R. Zuwallack,et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. , 1996, The American journal of medicine.
[133] S. Spencer,et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.
[134] Joseph Ornelas,et al. Methodologies for the development of CHEST guidelines and expert panel reports. , 2014, Chest.
[135] M. Thabane. Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. , 2012, Ontario health technology assessment series.
[136] G. Parr,et al. Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis. , 1987, British journal of diseases of the chest.
[137] J. Escarrabill,et al. Impact of a hospital-based home-care program on the management of COPD patients receiving long-term oxygen therapy. , 2001, Chest.
[138] J. Walters,et al. Action plans with limited patient education only for exacerbations of chronic obstructive pulmonary disease. , 2010, The Cochrane database of systematic reviews.
[139] Robert J Pierce,et al. Pilot study of remote telemonitoring in COPD. , 2012, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.
[140] Jiaquan Xu,et al. Deaths: final data for 2009. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[141] Michael K Gould,et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. , 2006, Archives of neurology.
[142] M. Cazzola,et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. , 2004, Pulmonary pharmacology & therapeutics.
[143] E. Walters,et al. Self-management education for patients with chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.
[144] V. Debari,et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study , 2008, International journal of clinical practice.
[145] M. Decramer,et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial , 2005, The Lancet.
[146] P. Anderson,et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial , 2001, The Lancet.
[147] M. Cazzola,et al. Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease , 2007, Expert opinion on therapeutic targets.
[148] Melanie Irvin-sellers,et al. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. , 2015, The Cochrane database of systematic reviews.
[149] Ramon Gisbert,et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. , 2002, Chest.
[150] I. Stiell,et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. , 2003, The New England journal of medicine.
[151] H. Rea,et al. A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease , 2004, Internal medicine journal.
[152] A. Boxall,et al. Managing chronic obstructive pulmonary disease in the community. A randomized controlled trial of home-based pulmonary rehabilitation for elderly housebound patients. , 2005, Journal of cardiopulmonary rehabilitation.
[153] E. Kerwin,et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. , 2013, Respiratory medicine.
[154] E. Wouters. Economic analysis of the Confronting COPD survey: an overview of results. , 2003, Respiratory medicine.
[155] S. Lam,et al. Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.
[156] D. Price,et al. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. , 2012, Primary care respiratory journal : journal of the General Practice Airways Group.
[157] N. Chavannes,et al. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. , 2009, Respiratory medicine.
[158] D. Sin,et al. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis , 2012, International journal of chronic obstructive pulmonary disease.
[159] S. Straus,et al. Lost in knowledge translation: Time for a map? , 2006, The Journal of continuing education in the health professions.
[160] P. Enright,et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials , 2011, BMJ : British Medical Journal.
[161] S. Spencer,et al. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2011, The Cochrane database of systematic reviews.
[162] R. Peto,et al. The natural history of chronic airflow obstruction. , 1977, British medical journal.
[163] Howard Balshem,et al. GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.
[164] P. Barnes. Development of new drugs for COPD. , 2013, Current medicinal chemistry.
[165] R. Zuwallack,et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. , 2003, Chest.
[166] R. Pauwels,et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.
[167] Harlan M. Krumholz,et al. A Taxonomy for Disease Management: A Scientific Statement From the American Heart Association Disease Management Taxonomy Writing Group , 2006, Circulation.
[168] N. Black,et al. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. , 1998, Journal of epidemiology and community health.
[169] E H Wagner,et al. Chronic disease management: what will it take to improve care for chronic illness? , 1998, Effective clinical practice : ECP.
[170] G. Marks,et al. Primary care Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease , 2022 .
[171] P. Van der valk,et al. Host-Pathogen Interaction during Pneumococcal Infection in Patients with Chronic Obstructive Pulmonary Disease , 2004, Infection and Immunity.
[172] A. Aggarwal,et al. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. , 2010, Chest.
[173] P. Lange,et al. Long‐term Effects of 1‐Year Maintenance Training on Physical Functioning and Health Status in Patients With COPD: A Randomized Controlled Study , 2010, Journal of cardiopulmonary rehabilitation and prevention.
[174] P. Poole,et al. Tiotropium versus placebo for chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.
[175] M. Martínez-García,et al. [Effectiveness of a specific program for patients with chronic obstructive pulmonary disease and frequent exacerbations]. , 2006, Archivos de bronconeumologia.
[176] M. Cazzola,et al. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease , 2013, Expert opinion on pharmacotherapy.
[177] G. Feldman,et al. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. , 2012, Pulmonary pharmacology & therapeutics.
[178] P. Jones,et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations , 2003, European Respiratory Journal.
[179] P. Wludyka,et al. A randomized trial of two types of nurse-assisted home care for patients with COPD. , 2005, Chest.
[180] T. Evald,et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. , 1994, Respiratory medicine.
[181] J. Lötvall,et al. Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial , 2012, BMJ Open.
[182] L. W. Jacobs,et al. THE IN VITRO REDUCTION IN VISCOSITY OF HUMAN TRACHEOBRONCHIAL SECRETIONS BY ACETYLCYSTEINE. , 2015, The American review of respiratory disease.
[183] Claudio Pedone,et al. Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: a randomized controlled trial , 2013, BMC Health Services Research.
[184] G. Pledger,et al. Tiotropium Respimat inhaler and the risk of death in COPD. , 2013, The New England journal of medicine.
[185] J. Izquierdo,et al. The burden of COPD in Spain: results from the Confronting COPD survey. , 2003, Respiratory medicine.
[186] N. Gross,et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. , 2008, Respiratory medicine.
[187] R. Sansores,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.
[188] Egon Toft,et al. Using preventive home monitoring to reduce hospital admission rates and reduce costs: a case study of telehealth among chronic obstructive pulmonary disease patients , 2012, Journal of telemedicine and telecare.
[189] M. Puhan,et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. , 2016, The Cochrane database of systematic reviews.
[190] R. Rodríguez-Roisín,et al. Toward a consensus definition for COPD exacerbations. , 2000, Chest.
[191] J. V. van Noord,et al. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD. , 2011, Pulmonary pharmacology & therapeutics.
[192] D. O’Donnell,et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease , 2004, European Respiratory Journal.
[193] D. Brooks,et al. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease--practical issues: a Canadian Thoracic Society Clinical Practice Guideline. , 2010, Canadian respiratory journal.
[194] A. Buist,et al. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. , 1999, The American journal of medicine.
[195] G. Colice. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. , 1996, The American journal of medicine.
[196] D. Niewoehner,et al. Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator , 2005, Annals of Internal Medicine.
[197] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[198] M. Cazzola,et al. Emerging drugs for chronic obstructive pulmonary disease , 2012, Expert opinion on emerging drugs.
[199] P. Bottrighi,et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. , 2004, Drugs under experimental and clinical research.
[200] P. Barnes. Glucocorticosteroids: current and future directions , 2011, British journal of pharmacology.
[201] P. Barnes,et al. Role of HDAC2 in the pathophysiology of COPD. , 2009, Annual review of physiology.
[202] N. Chavannes,et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. , 2013, The Cochrane database of systematic reviews.
[203] J. Hendy,et al. Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial , 2012, BMJ : British Medical Journal.
[204] E. Bateman,et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. , 2013, The Lancet. Respiratory medicine.
[205] Michelle E. Kho,et al. AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.
[206] J. V. van Noord,et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease , 2000 .
[207] S. Spencer,et al. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. , 2011, The Cochrane database of systematic reviews.
[208] M. Dueholm,et al. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. , 1992, Respiratory medicine.
[209] D. Altman,et al. Chapter 8: Assessing risk of bias in included studies , 2008 .
[210] M. Cazzola,et al. Emerging anti-inflammatory strategies for COPD , 2012, European Respiratory Journal.
[211] P. Casarosa,et al. Functional and Biochemical Rationales for the 24-Hour-Long Duration of Action of Olodaterol , 2011, Journal of Pharmacology and Experimental Therapeutics.
[212] K. Rabe,et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[213] B. Smith,et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.
[214] T. Seemungal,et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. , 2008, American journal of respiratory and critical care medicine.
[215] D. V. Hoff,et al. Tiotropium and the Risk of Death in COPD , 2014 .
[216] E. Bateman,et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study , 2013, European Respiratory Journal.
[217] P. Calverley,et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.
[218] A. Sharafkhaneh,et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. , 2012, Respiratory medicine.
[219] N. Wig,et al. Efficacy of two corticosteroid regimens in acute exacerbation of chronic obstructive pulmonary disease. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[220] J. Bourbeau,et al. Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease , 2007, Annals of Internal Medicine.
[221] K. Fagerström,et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy , 2006, European Respiratory Journal.
[222] Silvia Jiménez-Fernández,et al. Telemedicine Experience for Chronic Care in COPD , 2006, IEEE Transactions on Information Technology in Biomedicine.
[223] G. Guyatt,et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. , 2006, Chest.
[224] Jim Basilakis,et al. Home telecare study for patients with chronic lung disease in the Sydney West Area Health Service. , 2010, Studies in health technology and informatics.
[225] W. Banya,et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. , 2011, Pulmonary pharmacology & therapeutics.
[226] R. Casaburi,et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. , 2011, Respiratory medicine.
[227] B. Grant,et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. , 2002, The New England journal of medicine.
[228] S. Inglis,et al. Non‐pharmacological management interventions for COPD: an overview of Cochrane systematic reviews , 2013 .
[229] Y. Lacasse,et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. , 2008, Canadian respiratory journal.
[230] M. Miravitlles,et al. Clinical Outcomes and Cost Analysis of Exacerbations in Chronic Obstructive Pulmonary Disease , 2013, Lung.
[231] D. Hui,et al. Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis , 2013, PloS one.
[232] H. Magnussen,et al. Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. , 2000, Respiratory medicine.
[233] A. Sheikh,et al. The impact of a telemetric chronic obstructive pulmonary disease monitoring service: randomised controlled trial with economic evaluation and nested qualitative study. , 2009, Primary Care Respiratory Journal.
[234] J. Crowley,et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. , 1996, American journal of respiratory and critical care medicine.
[235] W. Bailey,et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. , 2000, American journal of respiratory and critical care medicine.
[236] D. Malone,et al. Statin use and risk of COPD exacerbation requiring hospitalization. , 2013, The American journal of medicine.
[237] F. Jódar-Sánchez,et al. Implementation of a Telehealth Programme for Patients with Severe Chronic Obstructive Pulmonary Disease Treated with Long-Term Oxygen Therapy , 2013, Journal of telemedicine and telecare.
[238] J. McElnay,et al. Clinical pharmacy-led disease and medicine management programme for patients with COPD. , 2009, British journal of clinical pharmacology.
[239] T. Iwanaga,et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. , 2008, Vaccine.
[240] A. Anzueto,et al. Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes , 2009, COPD.
[241] Tzeng-Ji Chen,et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. , 2011, Clinical therapeutics.
[242] M. Hyland,et al. Efficient integrated education for older patients with chronic obstructive pulmonary disease using the Lung Information Needs Questionnaire , 2011, Geriatrics & gerontology international.
[243] J. Hallas,et al. Nurse tele‐consultations with discharged COPD patients reduce early readmissions – an interventional study , 2011, The clinical respiratory journal.
[244] N. Hanania,et al. The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD , 2003 .
[245] Aziz Sheikh,et al. Telehealthcare for chronic obstructive pulmonary disease. , 2011, The Cochrane database of systematic reviews.
[246] P. Jones,et al. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. , 2011, Respiratory medicine.
[247] F. Blackstock,et al. Disease-specific health education for COPD: a systematic review of changes in health outcomes. , 2006, Health education research.
[248] L. Raiteri,et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. , 2014, The Lancet. Respiratory medicine.
[249] R. Wood‐Baker,et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.
[250] C. Dowson,et al. Self‐management plans in the primary care of patients with chronic obstructive pulmonary disease , 2006, Respirology.
[251] Thomas Bodenheimer,et al. Improving primary care for patients with chronic illness: the chronic care model, Part 2. , 2002, JAMA.
[252] S. Scalvini,et al. Tele-assistance in chronic respiratory failure patients: a randomised clinical trial , 2008, European Respiratory Journal.
[253] Elizabeth M. Borycki,et al. Reduction of Hospital Utilization in Patients With Chronic Obstructive Pulmonary Disease: A Disease-Specific Self-management Intervention , 2003 .
[254] E. Silverman,et al. Predictors of survival in severe, early onset COPD. , 2004, Chest.
[255] R. Jiménez-García,et al. Inappropriate Overuse of Inhaled Corticosteroids for COPD Patients: Impact on Health Costs and Health Status , 2011, Lung.
[256] Grant D. Huang,et al. A Comprehensive Care Management Program to Prevent Chronic Obstructive Pulmonary Disease Hospitalizations , 2012, Annals of Internal Medicine.
[257] M. Miravitlles,et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. , 2001, Chest.
[258] S. Yancey,et al. Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.
[259] D. O’Donnell,et al. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.
[260] M. Polkey,et al. Outpatient pulmonary rehabilitation following acute exacerbations of COPD , 2010, Thorax.
[261] T. Lasserson,et al. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. , 2006, The Cochrane database of systematic reviews.
[262] L. Merz,et al. P154 Development of the Documentation And Appraisal Review Tool (Dart) For Systematic Reviews , 2013 .
[263] A. Monto. Influenza: quantifying morbidity and mortality. , 1987, The American journal of medicine.
[264] M. Cazzola,et al. Emerging inhaled bronchodilators: an update , 2009, European Respiratory Journal.
[265] D. Niewoehner,et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. , 1999, The New England journal of medicine.
[266] E. Bleecker,et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. A 90-day multi-center study. , 1986, The American journal of medicine.
[267] Thierry Troosters,et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. , 2013, American journal of respiratory and critical care medicine.
[268] T. Ten Have,et al. Outcomes of a telehealth intervention for homebound older adults with heart or chronic respiratory failure: a randomized controlled trial. , 2012, The Gerontologist.
[269] N. Murphy,et al. Extending a home from hospital care programme for COPD exacerbations to include pulmonary rehabilitation. , 2005, Respiratory medicine.
[270] C. Taube,et al. Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease. , 2011, Pulmonary pharmacology & therapeutics.
[271] D. Au,et al. The Effects of Smoking Cessation on the Risk of Chronic Obstructive Pulmonary Disease Exacerbations , 2009, Journal of General Internal Medicine.
[272] J. DiNicolantonio,et al. Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[273] L. Fabbri,et al. Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients , 2010, COPD.
[274] R. Zuwallack,et al. An official American Thoracic Society workshop report: the Integrated Care of The COPD Patient. , 2012, Proceedings of the American Thoracic Society.
[275] C. Howells,et al. Prophylactic use of influenza vaccine in patients with chronic bronchitis. A pilot trial. , 1961, Lancet.
[276] G. Della Cioppa,et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. , 2002, Chest.
[277] M. Esteva,et al. Efficacy of pulmonary rehabilitation in patients with moderate chronic obstructive pulmonary disease: a randomized controlled trial , 2013, BMC Family Practice.
[278] M. Cazzola,et al. β2‐adrenoceptor agonists: current and future direction , 2011, British journal of pharmacology.
[279] G. Paré,et al. Comparing the costs of home telemonitoring and usual care of chronic obstructive pulmonary disease patients: A randomized controlled trial , 2013 .
[280] A. Buist,et al. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. The COMBIVENT Inhalation Solution Study Group. , 1997, Chest.
[281] V. Brusasco,et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.
[282] J. Steurer,et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. , 2009, The Cochrane database of systematic reviews.
[283] M. Polkey,et al. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study , 2004, BMJ : British Medical Journal.
[284] Thomas Bodenheimer,et al. Improving primary care for patients with chronic illness. , 2002, JAMA.